Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab

Status unconfirmed · Phase 2 · Has a placebo group

Conditions studied: Atopic Dermatitis

In brief

Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.

Key facts

Study ID: NCT05694884
Run by: ASLAN Pharmaceuticals
People needed: 75
Starts: 2022-12-21
Expected to finish: 2025-02-28
Last updated by the study team: 2024-01-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Male or female participants ≥18 years
Willing and able to comply with clinic visits and study-related procedures
Chronic AD present for at least 1 year prior to screening
Have vIGA score of ≥3 (5-scale of 0 to 4) at baseline
Have ≥10% BSA of AD involvement at baseline
Have EASI ≥18 at screening and baseline
History of inadequate response to, intolerance to or contraindication to a stable regimen of topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) as treatment for AD
All participants must have previously been treated with dupilumab meeting one of the following conditions:
Participants who stopped dupilumab treatment due to non-response, partial response, loss of efficacy must have been previously treated with dupilumab for at least 16 weeks duration;
Participants who stopped dupilumab treatment due to intolerance or adverse events (AEs) to the drug may enter the study with no required prior length of dupilumab treatment;
Participants who stopped dupilumab treatment due to cost or loss of access to dupilumab or for any other reasons may enter the study with no required prior length of dupilumab treatment;

You may not qualify if…

Use of immunosuppressive/immunomodulating drugs and/or therapies, JAK inhibitors, or phototherapy (including tanning booth/parlor) within 4 weeks prior to the Baseline visit
Have an uncontrolled chronic disease that may require multiple intermittent use of systemic corticosteroids at Screening, as defined by the Investigator
Have uncontrolled asthma that might require bursts of oral or systemic corticosteroids, or require either of the following due to ≥1 exacerbations within 12 months before Baseline:
Systemic (oral and/or parenteral) corticosteroid treatment;
Hospitalization for >24 hours;
Have had systemic treatment with small molecule investigational drugs within 8 weeks or 5 half-lives (if known), whichever is longer, prior to the Baseline visit
Have received treatment with topical corticosteroids (TCS), topical calcineurin inhibitors (TCI) such as tacrolimus and pimecrolimus, topical phosphodiesterase inhibitors such as crisaborole, topical JAK inhibitors (commercial or investigational use), within 1 week prior to randomization
Have inadequate organ function or abnormal lab results considered clinically significant by the Investigator at the Screening visit
History of human immunodeficiency virus (HIV) or positive HIV serology at Screening
Infected with hepatitis B or hepatitis C viruses. For Hepatitis B, all subjects will undergo testing for Hepatitis B Surface Antigen (HBsAg) and Hepatitis B Core Antibody (HBcAb) during Screening. Subjects who are HBsAg positive are not eligible for the study. Subjects who are HBsAg negative and HBcAb positive will be tested for Hepatitis B Surface Antibody (HBsAb) and if HBsAb is positive, may be enrolled in the study; if HBsAb is negative, the subject is not eligible for the study. For Hepatitis C, all subjects will undergo testing for Hepatitis C antibody (HCVAb) during Screening. Subjects who are HCVAb positive are not eligible for the study. Active COVID-19 infection at Baseline.
Have known liver cirrhosis and/or chronic hepatitis of any etiology
Known diagnosis of active tuberculosis or non-tuberculous mycobacterial infection or latent tuberculosis unless it is well documented by a specialist that the patient has been adequately treated
Allergen immunotherapy should be discontinued 6 months before randomization

Where it is running

ASLAN Investigative Site — Birmingham, Alabama, United States (enrolling)
ASLAN Investigative Site — Encino, California, United States (enrolling)
ASLAN Investigative Site — Fountain Valley, California, United States (enrolling)
ASLAN Investigative Site — Long Beach, California, United States (enrolling)
ASLAN Investigative Site — Los Angeles, California, United States (enrolling)
ASLAN Investigative Site — Sherman Oaks, California, United States (enrolling)
ASLAN Investigative Site — Boca Raton, Florida, United States (enrolling)
ASLAN Investigative Site — Hollywood, Florida, United States (enrolling)
ASLAN Investigative Site — Hollywood, Florida, United States (enrolling)
ASLAN Investigative Site — Miami Lakes, Florida, United States (enrolling)
ASLAN Investigative Site — North Miami Beach, Florida, United States (enrolling)
ASLAN Investigative Site — Orange City, Florida, United States (enrolling)
ASLAN Investigative Site — Saint Augustine, Florida, United States (enrolling)
ASLAN Investigative Site — St. Petersburg, Florida, United States (enrolling)
ASLAN Investigative Site — New Albany, Indiana, United States (enrolling)
ASLAN Investigative Site — Louisville, Kentucky, United States (enrolling)
ASLAN Investigative Site — Quincy, Massachusetts, United States (enrolling)
ASLAN Investigative Site — Auburn Hills, Michigan, United States (enrolling)
ASLAN Investigative Site — Las Vegas, Nevada, United States (enrolling)
ASLAN Investigative Site — East Amherst, New York, United States (enrolling)
ASLAN Investigative Site — Charlotte, North Carolina, United States (enrolling)
ASLAN Investigative Site — Oklahoma City, Oklahoma, United States (enrolling)
ASLAN Investigative Site — Johnston, Rhode Island, United States (enrolling)
ASLAN Investigative Site — Charleston, South Carolina, United States (enrolling)
ASLAN Investigative Site — Hamilton, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.